D.E. Shaw & Co’s Myriad Genetics MYGN Stock Holding History
Bought
Maintained
Sold
Other funds holding MYGN
D.E. Shaw & Co's MYGN Position: Q3 2026 in Review
D.E. Shaw & Co increased its Myriad Genetics (MYGN) stake by 2.3% in Q3 2026, buying an estimated $441K and bringing the position to 4,686,766 shares worth $20.2M. The position accounts for 0.01% of the portfolio, ranked #1299.
D.E. Shaw & Co first reported a position in MYGN in Q2 2013 and has held it in 54 quarters since. The position peaked at $179M in Q3 2018. 176 funds tracked by Wall St. Rank hold MYGN as of Q3 2026.
- D.E. Shaw & Co held 4,686,766 shares of Myriad Genetics worth $20.2M as of Q3 2026.
- D.E. Shaw & Co bought 104,683 Myriad Genetics shares in Q3 2026, an estimated $441K.
- Myriad Genetics made up 0.01% of D.E. Shaw & Co's portfolio in Q3 2026, its #1299 holding.
- D.E. Shaw & Co first reported a position in Myriad Genetics in Q2 2013 and has held it in 54 quarters since.
- D.E. Shaw & Co's Myriad Genetics position peaked at $179M in Q3 2018.
- 176 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2026.
Based on D.E. Shaw & Co's 13F filing for Q3 2026, filed 16 Nov 2026.